Artificial Intelligence | Machine Learning | Natural Language Processing Ordaos Bio | Mini-Proteins for Drug Hunters Treatments


Enterprise, Health Assistant, Drug Research & Development, Drug Discovery New York , United States

Ordaos Bio

Artificial Intelligence | Machine Learning | Natural Language Processing


Ordaos Bio | Mini-Proteins for Drug Hunters Treatments

Ordaos Bio

Health Assistant, Drug Research & Development, Drug Discovery


New York , United States

Orda?s is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods. For each client, we create billions of proteins and evaluate their properties in silico to reliably and repeatedly deliver the de novo mini-proteins that drug hunters only dream of. We then prove our consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery. We help birth novel therapies to reduce patient suffering and improve health. We deliver safer and more effective life-saving treaments. Our flagship solution, miniPRO™ proteins, enable drug hunters to deliver safer and more effective treatments in a fraction of the time of traditional discovery methods. Orda?s miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to scale-up and manufacture. These proteins are 20x smaller than traditional monoclonal antibodies enabling them to more easily penetrate and effectively treat disease microenvironments. miniPRO™ proteins make up a group of 40~160 amino acid long proteins that independently fold into single domains. The proteins act as self-contained, configurable building blocks and are engineered for the therapeutic modality of choice. We are a human-enabled, machine-driven drug design company that creates bespoke mini-proteins to help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. Our deep learning approach goes beyond rational combinatorial methods. We leverage a generative perception engine powered by reinforcement learning and proprietary data sets to translate human-targeted product criter

 
 

   Total Funding: $10.6M

   Funding Stage: Seed

   Business Stage: Scaling Up

   Market: B2B

   Company Size: 26 to 50

   Founded: 2019

Apr 2022

  • Ordaos Bio Collaborated with Vyant Bio, Inc., and Cellaria, Inc.
 
 

Date

Round

$ Raised

Investors

08/26/2022

Seed

$5M

VTC Ventures, Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, Citta Capital

Date : 08/26/2022

Round: Seed

$ Raised: $5M

Investors: VTC Ventures, Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, Citta Capital

 

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Ordaos Bio

 
 
 
David Longo

David Longo
Chief Executive Officer

Tim Shelburne

Tim Shelburne
Chief Product Officer / Acting Chief Technology Officer

Georgina Colquhoun

Georgina Colquhoun
Vice President Of Business Development

 
 

Ordaos Bio is growing. Want to work at Ordaos Bio? Ordaos Bio is hiring. Join team at Ordaos Bio

 
 
appengine.ai

World's Most Promising AI/ML Startups